- 11
- 6 162
SINAPPS Group
United Kingdom
Registrace 21. 05. 2020
SINAPPS stands for Study of Immunology in Antibody Positive Psychosis.
We are a research group formed of collaborating Universities in the UK, investigating the role of immunotherapy and autoimmune antibodies as a cause of psychosis.
We are a research group formed of collaborating Universities in the UK, investigating the role of immunotherapy and autoimmune antibodies as a cause of psychosis.
The SINAPPS2 Clinical Trial - Treating psychosis with immunotherapy ?
To find out more about the SINAPPS2 Trial please click here:
www.psych.ox.ac.uk/research/autoimmune-psychosis
Psychotic illnesses like schizophrenia and bipolar disorder are serious mental illnesses of unknown cause. There is an urgent need to discover the basis of these disorders, and to develop new treatments. There are many lines of evidence to suggest that a proportion of psychosis has an immune basis. We are a multidisciplinary group of clinicians and researchers who are exploring this possibility, using a range of approaches.P
We have found that some people with psychosis have particular antibodies that are known to cause another serious brain disorder - encephalitis. It is possible that these same antibodies are also causing psychosis in some people, and we are undertaking research to establish whether this is the case.
We undertake clinical trials of immune therapies in people with psychosis, and experimental medicine studies to examine the interaction between the immune system and the brain.
We propose that in some patients the cause of psychosis may be antibodies binding to neuronal membrane targets (NMDAR, LGI1, GABA-A and other), especially NMDA receptors, in the brain. The hypothesis underlying the SINAPPS2 trial is that these antibodies may be pathogenic and responsible for isolated psychosis (antibody-mediated psychosis).
We are currently conducting the SINAPPS2 trial to test whether immunotherapy is an effective treatment for antibody-associated psychosis. It is a randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulin and rituximab in patients with antibody-associated psychosis. Adult patients (16-60 years old) with antibody-associated psychosis are invited to one of the NHS hospitals participating in the study, where they are assessed and assisted by a team of SINAPPS2 clinicians and researchers. Eligible patients are randomly allocated to receive either intravenous immunoglobulin combined with rituximab or placebo treatment and they will be followed for at least 12 months
www.psych.ox.ac.uk/research/autoimmune-psychosis
Psychotic illnesses like schizophrenia and bipolar disorder are serious mental illnesses of unknown cause. There is an urgent need to discover the basis of these disorders, and to develop new treatments. There are many lines of evidence to suggest that a proportion of psychosis has an immune basis. We are a multidisciplinary group of clinicians and researchers who are exploring this possibility, using a range of approaches.P
We have found that some people with psychosis have particular antibodies that are known to cause another serious brain disorder - encephalitis. It is possible that these same antibodies are also causing psychosis in some people, and we are undertaking research to establish whether this is the case.
We undertake clinical trials of immune therapies in people with psychosis, and experimental medicine studies to examine the interaction between the immune system and the brain.
We propose that in some patients the cause of psychosis may be antibodies binding to neuronal membrane targets (NMDAR, LGI1, GABA-A and other), especially NMDA receptors, in the brain. The hypothesis underlying the SINAPPS2 trial is that these antibodies may be pathogenic and responsible for isolated psychosis (antibody-mediated psychosis).
We are currently conducting the SINAPPS2 trial to test whether immunotherapy is an effective treatment for antibody-associated psychosis. It is a randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulin and rituximab in patients with antibody-associated psychosis. Adult patients (16-60 years old) with antibody-associated psychosis are invited to one of the NHS hospitals participating in the study, where they are assessed and assisted by a team of SINAPPS2 clinicians and researchers. Eligible patients are randomly allocated to receive either intravenous immunoglobulin combined with rituximab or placebo treatment and they will be followed for at least 12 months
zhlédnutí: 3 763
Video
SINAPPS group webinar series 'Inflammation and Psychosis: an update': Professor Angela Vincent
zhlédnutí 186Před 3 lety
SINAPPS group webinar series episode 10 Professor Angela Vincent, Emeritus Professor of Neuroimmunology, Nuffield Department of Clinical Neurosciences at University of Oxford and Honorary Professor at University College London presents 'Maternal Immunity and Neurodevelopment: a neglected field?'' Chair: Isobel Harrison For more information on this topic visit our website sinapps.org.uk Intro an...
SINAPPS group webinar series 'Inflammation and Psychosis: an update': Dr Esther Coutinho
zhlédnutí 315Před 3 lety
SINAPPS group webinar series episode 9 Dr Esther Coutinho, Consultant Neurologist at Kings College Hospital and Clinical Research Fellow in the Department of Basic & Clinical Neuroscience at Kings College London presents 'The patients who changed the field of autoimmune neurology' Chair: Isobel Harrison For more information on this topic visit our website sinapps.org.uk Intro and outro music co...
SINAPPS group webinar series 'Inflammation and Psychosis: an update': Dr Sarah Crisp
zhlédnutí 102Před 3 lety
SINAPPS group webinar series episode 8 Dr Sarah Crisp, Neurologist and NIHR clinical lecturer in Clinical Neurosciences at University of Cambridge presents 'Stiff people and their antibodies' Chairs: Isobel Harrison and Iona Cairns For more information on this topic visit our website sinapps.org.uk Intro and outro music courtesy of Bensound.com
SINAPPS group webinar series 'Inflammation and Psychosis: an update': Dr Jonathan Rogers
zhlédnutí 132Před 3 lety
SINAPPS group webinar series episode 7 Dr Jonathan Rogers, wellcome trust clinical training fellow at UCL and speciality registrar at South London and Maudsley NHS Foundation Trust presents 'Catatonia, infection and immunity.' Chairs: Isobel Harrison and Dr Ksenija Yeeles For more information on this topic visit our website sinapps.org.uk Intro and outro music courtesy of Bensound.com
SINAPPS group webinar series 'Inflammation and Psychosis: an update': Professor Peter Jones
zhlédnutí 186Před 4 lety
INAPPS group webinar series episode 6. Professor Peter Jones, professor of psychiatry at the University of Cambridge and consultant psychiatrist at the Cambridgeshire and Peterborough NHS Foundation Trust, presents the talk 'Neurodevelopmental precursors of psychosis and their relevance to clinical practice' Chairs: Giuliano Tomei, Danielle Smith, Isobel Harrison For more information on this to...
SINAPPS group webinar series 'Inflammation and Psychosis: an update': Professor Michael Zandi
zhlédnutí 364Před 4 lety
SINAPPS group webinar series episode 5. Professor Michael Zandi, consultant neurologist at the National Hospital for Neurology and Neurosurgery and honorary associate professor at the University College London, presents the talk 'Encephalitis and Psychosis - lessons from encephalitis lethargica to COVID-19' Chairs: Giuliano Tomei, Danielle Smith, Isobel Harrison For more information on this top...
SINAPPS group webinar series 'Inflammation and Psychosis: an update': Professor Eileen Joyce
zhlédnutí 196Před 4 lety
SINAPPS group webina series episode 4. Professor Eileen Joyce, Professor of Neuropsychiatry at UCL, discusses the role of inflammation in first episode psychosis cognitive impairment. Chairs: Giuliano Tomei, Danielle Smith For more information on this topic visit our website sinapps.org.uk Intro and outro music courtesy of Bensound.com
SINAPPS group webinar series 'Inflammation and Psychosis: an update': Dr Thomas Kabir
zhlédnutí 142Před 4 lety
SINAPPS group webina series episode 3. Dr Thomas Kabir, lead of the Public Involvement in Research programme at the McPin Foundation, discusses the ethical and legal issues surrouding capacity of psychiatric patients to consent to participate in research. Chairs: Danielle Smith, Isobel Harrison For more information on this topic visit our website sinapps.org.uk Intro and outro music courtesy of...
SINAPPS group webinar series 'Inflammation and Psychosis: an update': Professor Alasdair Coles
zhlédnutí 174Před 4 lety
SINAPPS group webina series episode 2. Professor Alasdair Coles, University of Cambridge, discusses the potential use of immunotherapy in psychiatric patients with psychosis and its implications for clinical practice. Chairs: Giuliano Tomei, Isobel Harrison For more information on this topic visit our website sinapps.org.uk Intro and outro music courtesy of Bensound.com
SINAPPS group webinar series 'Inflammation and Psychosis: an update': Professor Belinda Lennox
zhlédnutí 605Před 4 lety
SINAPPS group webina series episode 1. Professor Belinda Lennox, University of Oxford, discusses the clinical presentation of psychiatric patients with antineuronal antibodies, and its implications for clinical practice. Chairs: Giuliano Tomei, Danielle Smith For more information on this topic visit our website sinapps.org.uk Intro and outro music courtesy of Bensound.com
Update
What is the exact bloodwork test to have done? In the US
I wish I could be one of these patients, my life is over
I would love to participate with in it Please let me know how this is possible since I live in another country. Could I contact you and talk about it Please . It is hard with this type of illness.Thank you
he SAD thing is you are not testing people enough WHAT ARE THE ROOT causes. Everybody is different. Some may have post trauma from a childhood Some some bad parasites even in the brain Some heavy metal even in the brain ...some hormonal imbalances ..NON of those are ever checked. They just look at person and judge...They just pull the blood for same and same testing...It is SAD. We know how to send the satellite to Mars and find out what component of the soil is there and we"DON"T KNOW " the causes Come on Isn't about time to start to look for the root causes? I learn that in those people there are a lot of not necessary white blood cells in the brain I have learned that bone marrow transplant is helping Why it is not being studied? I found out that people receiving a blood transfusion from people so called "mentally ill" are developing psychosis. Good lock to take someone blood from unknown resources. My aunt developed dementia after she was served with someones blood
Would you please give the name of the blood test that would determine the presence of the antibodies. I'm in the US.
What about skitzophrenia
What about people with long term chronic psychosis that meds have not helped ? If in USA how could we get tested to see if this may be helpful ?
What type of treatment is given? Whats the basis of it? The science behind it?
Dear Leslie, Apologies for taking us long to reply. The SINAPPS2 clinical trial is testing efficacy of IVIG and Rituximab for people with antibody associated psychosis. You can find more info on our clinical trial and scientific background on our website www.sinapps.org.uk The list of relevant published papers is available in Resources. Best wishes, SINAPPS2 Research Group
Is this trial still going?
HI, The trial is still ongoing. Best wishes, SINAPPS Research team
@@sinappsgroup7418 one year has passed, is the trial done?
I am curious to know how Ed is doing now?
Hi, Ed is doing well. Best wishes, SINAPPS Research team
Markers of chronic low grade inflammation are raised across neuropsychiatric disorders. Immunotherapy is a good next step in addressing the treatment gaps prevalent in neuropsychiatric care. I use minocycline in my practice in India to Rx negative symptoms. It targets astrocytes. Hopefully, we get to use MABs and IVIGs in psychosis.
Hello doctor Kulkarni I am trying to find a doctor in India that understands immune system's role in schizophrenia and can treat it from this angle. How can I reach you?
@@yogeshsoni4558first of all he dont know how to treat with that new treatment because he said so although all tools required are in india and the guidlines of the new treatment is available online. if he neglected to answer you 3 months or he is ignorant to know he has a notification (iliterate about technology ) then he is a harmfull doctor. His comment is just a social small talk with a little man time waster who have been denied to give him a word in responce
I hope you Realize this is Not a regular Psychosis?!
This artical is misleading! This is Not a psychosis trestment! Its against auto immune psychosis Not many have that. And minocycline has alot of sideffekts!!! Betten use ulotaront and xanomeline next year.
@@classic2620 thanks for your words.
is the covid19 getting in the way of here work